dipeptidyl
peptidas
iv
dppiv
membranebound
serin
proteas
preferenti
cleav
peptid
bond
penultim
prolin
residu
catalyt
domain
locat
extracellularli
anchor
membran
singl
transmembran
domain
dppiv
dimer
essenti
enzymat
activ
substrat
dppiv
small
oligopeptid
includ
hormon
chemokin
neuropeptid
dppiv
ubiquit
express
variou
tissu
interestingli
enzymat
activ
dppiv
reduc
sera
patient
melanoma
oral
cancer
attenu
dppiv
express
cell
surfac
also
observ
malign
cell
melanoma
lung
nonadenocarcinoma
melanocyt
elimin
dppiv
occur
concomitantli
growth
factor
independ
reexpress
dppiv
melanoma
cell
suppress
malign
phenotyp
melanocyt
cell
human
nonadenocarcinoma
cancer
enzymat
activ
express
dppiv
dramat
reduc
compar
normal
bronchial
lung
alveolar
epithelia
interestingli
reexpress
dppiv
lung
cancer
cell
inhibit
tumor
event
cell
prolifer
anchorageindepend
growth
migrat
tumorigen
nude
mice
mechan
dppiv
downregul
tumor
growth
tissu
yet
clear
insulinlik
growth
factor
power
mitogen
stimul
cell
prolifer
singl
polypeptid
amino
acid
bind
receptor
high
affin
biolog
function
mediat
tyrosin
kinas
signal
phosphoryl
sever
downstream
adaptor
protein
thu
activ
distinct
downstream
signal
pathway
includ
akt
raf
mapk
pathway
physiolog
concentr
tightli
regul
total
concentr
blood
nm
concentr
control
igfbind
protein
igfbp
bind
free
among
main
protein
abund
high
affin
remain
free
constitut
less
total
concentr
given
tight
bind
igfbp
nm
sequest
igfbp
effect
reduc
amount
avail
activ
way
igfbp
neg
regul
bioavail
studi
found
proteolyt
process
enzym
dppiv
result
truncat
form
shorten
two
amino
acid
less
potent
activ
bind
tightli
quantit
also
show
dppiv
express
significantli
downregul
human
lung
squamou
cell
carcinoma
scc
tissu
compar
adjac
nonneoplast
lung
tissu
studi
suggest
new
interest
link
dppiv
develop
cancer
specif
tumor
nich
obtain
peprotech
asia
usa
insulin
receptor
cell
signal
technolog
inc
danver
antiinsulin
antiphosphoinsulin
santa
cruz
biotechnolog
santa
cruz
ca
abcam
cambridg
uk
polypeptid
gpetlcgael
synthes
kelowna
intern
scientif
taiwan
matrixassist
laser
desorpt
flight
mass
spectrometri
analysi
carri
mass
core
facil
nrpgm
nation
scienc
council
taiwan
cell
gift
dr
yang
pangchyr
nation
taiwan
univers
cell
purchas
american
type
cultur
collect
cultur
accord
instruct
ensur
puriti
dppiv
fap
affin
chromatographi
ion
exchang
chromatographi
andor
gel
filtrat
chromatographi
use
isol
pure
proteas
dppiv
purifi
baculovirusinfect
insect
cell
describ
previous
ammonium
sulfat
ad
medium
contain
secret
dppiv
satur
precipit
resuspend
mm
sodium
phosphat
buffer
contain
mm
nacl
solut
pass
nickel
affin
column
column
wash
mm
imidazol
sampl
elut
mm
imidazol
buffer
contain
mm
sodium
phosphat
addit
purif
perform
ion
exchang
gel
filtrat
chromatographi
fap
express
plasmid
insect
cell
construct
describ
previous
fap
purifi
bind
resin
novagen
hitrap
q
sepharos
ff
ge
healthcar
specif
cultur
medium
high
fivetm
cell
express
fap
collect
protein
precipit
addit
ammonium
sulfat
satur
pellet
resuspend
bind
buffer
mm
trishcl
buffer
contain
mm
nacl
pass
column
bed
volum
bind
buffer
mm
mm
imidazol
use
wash
column
time
fap
protein
elut
mm
imidazol
bind
buffer
eluat
chang
buffer
mm
trishcl
amicon
devic
millipor
sampl
load
onto
hitrap
q
sepharos
ff
column
final
fap
protein
elut
mm
nacl
gradient
buffer
puriti
protein
determin
coomassi
blue
stain
protein
concentr
determin
bradford
method
use
bovin
serum
albumin
bsa
standard
dppiv
fap
incub
peptid
assay
buffer
mm
trishcl
ph
overnight
reaction
termin
addit
acet
acid
sampl
subject
highperform
liquid
chromatographi
hplc
andor
analysi
describ
previous
confirm
mass
analysi
kinet
paramet
determin
publish
method
assay
initi
veloc
given
function
enzym
concentr
e
follow
equat
vkcat
e
substrat
concentr
kept
constant
enzym
concentr
vari
larg
excess
substrat
maintain
differ
concentr
purifi
dppiv
incub
nm
assay
buffer
mm
trishcl
final
volum
time
cours
min
end
incub
period
reaction
stop
acet
acid
total
volum
sampl
subject
analysi
peak
area
quantifi
flexanalysi
bruker
daltonik
gmbh
bremen
germani
amount
calcul
measur
peak
area
compar
control
initi
veloc
calcul
amount
obtain
differ
time
point
kinet
paramet
analyz
use
new
equat
shown
cell
serum
starv
overnight
fresh
serumfre
medium
ad
cell
incub
h
addit
differ
concentr
incub
cell
lyse
ripa
buffer
mm
nacl
mm
tri
sd
triton
deoxychol
mm
edta
contain
proteas
inhibitor
cocktail
roch
phosphatas
inhibitor
cocktail
sigma
lysat
clarifi
centrifug
quantifi
bradford
assay
mix
boil
load
buffer
mm
trishcl
bromophenol
blue
glycerol
fraction
sd
polyacrylamid
gel
protein
transfer
polyvinyliden
difluorid
membran
western
blot
probe
antibodi
indic
imag
analyz
quantifi
adob
photoshop
use
method
outlin
http
enzymelink
immunosorb
assay
elisa
use
describ
previous
determin
rel
bind
capac
elisa
plate
coat
overnight
either
nm
nm
intact
fap
protein
mix
intact
form
use
control
excess
antigen
remov
overnight
incub
nonspecif
bind
site
block
incub
bsa
pb
room
temperatur
h
follow
three
wash
pb
ng
mm
trishcl
contain
bsa
ad
well
incub
h
gentl
shake
unbound
remov
wash
sampl
three
time
pb
plate
incub
h
antibodi
dilut
pb
wash
three
time
pb
horseradishperoxidaseconjug
antimous
igg
dilut
ad
well
plate
incub
anoth
h
well
wash
three
time
pb
plate
treat
tetramethylbenzidin
substrat
absorb
determin
spectrophotometr
nm
rel
bind
capac
express
percentag
absorb
nm
intact
truncat
rel
control
differ
concentr
statist
analysi
perform
student
test
quantit
perform
accord
publish
protocol
tumor
adjac
nonneoplast
tissu
dissect
lung
patient
scc
adenocarcinoma
adc
obtain
changgung
memori
hospit
taiwan
accord
institut
guidelin
rna
convert
cdna
impromiitm
revers
transcriptas
promega
quantit
pcr
perform
abi
prism
sequenc
detect
system
use
sybr
green
pcr
master
mix
abi
sequenc
primer
use
quantit
dppiv
gapdh
cycl
threshold
ct
dppiv
calcul
normal
constant
deriv
correct
gapdh
describ
previous
statist
analysi
perform
student
test
determin
whether
dppiv
cleav
extra
precaut
taken
ensur
puriti
protein
use
studi
materi
method
purifi
protein
activ
similar
report
previous
fap
proteas
highli
homolog
dppiv
sequenc
ident
structur
similar
therefor
cleavag
fap
also
investig
first
peptid
gpetlcgael
first
amino
acid
nterminu
incub
dppiv
hplc
analysi
identifi
dipeptid
octapeptid
etlcgael
product
dppiv
digest
fig
ident
two
cleavag
product
confirm
malditof
mass
spectrometri
data
shown
reaction
condit
fap
cleav
gpetlcgael
data
shown
next
investig
whether
dppiv
cleav
fulllength
molecular
mass
dalton
fig
incub
dppiv
molecular
mass
decreas
dalton
correspond
delet
dipeptid
amino
terminu
fig
molecular
mass
chang
incub
fap
fig
data
indic
dppiv
specif
cleav
nterminu
produc
dipeptid
kinet
paramet
cleavag
dppiv
measur
digest
dppiv
slow
specif
protocol
use
quantifi
enzymat
reaction
initi
veloc
measur
linear
rang
reaction
mass
identif
quantif
materi
method
kcatkm
valu
cleavag
dppiv
km
kcat
equal
respect
base
kinet
paramet
cleavag
effici
cleavag
matrix
metalloproteinas
mmp
report
previous
micromolar
level
km
valu
similar
cleavag
gip
dppiv
therefor
cleavag
dppiv
physiolog
relev
despit
slow
reaction
indic
kcat
valu
signal
transduct
igf
signal
pathway
initi
activ
studi
interact
intact
activ
first
investig
differ
human
lung
cancer
cell
line
includ
wellstudi
lung
adc
cell
line
lung
scc
cell
line
cell
two
largecel
carcinoma
cell
line
express
abundantli
cell
line
studi
except
interestingli
activ
detect
cell
presenc
nm
stimul
min
fig
weak
activ
detect
cell
fig
therefor
cell
select
studi
activ
intact
truncat
concentr
nm
increas
phosphoryl
tyr
cell
compar
untreat
control
lane
b
fig
cell
treat
purifi
dppiv
lane
fig
shown
fig
phosphoryl
significantli
reduc
cell
treat
nm
nm
physiolog
concentr
signific
differ
activ
concentr
higher
physiolog
level
nm
nm
fig
result
indic
less
potent
intact
activ
differ
phosphoryl
downstream
akt
erk
either
ad
concentr
test
fig
tempor
respons
determin
fig
intact
nm
phosphoryl
reach
optim
level
min
stimul
sustain
min
decreas
min
fig
three
hour
stimul
increas
phosphoryl
remain
detect
fig
howev
similar
concentr
peak
level
activ
reach
min
follow
larg
drop
min
fig
activ
observ
h
fig
ad
concentr
higher
physiolog
level
nm
level
phosphoryl
caus
indistinguish
subsequ
h
result
shown
fig
suggest
activ
delay
sustain
major
protein
sequest
rel
bind
affin
determin
elisa
shown
fig
amount
bind
time
greater
amount
bind
data
indic
bind
affin
stronger
therefor
sequest
effect
cognat
given
truncat
dppiv
affect
activ
next
investig
express
level
dppiv
human
nonsmallcel
lung
cancer
tissu
quantit
six
patient
lung
adc
six
patient
lung
scc
one
specimen
taken
cancer
tissu
anoth
adjac
nonneoplast
tissu
quantit
show
dramat
reduct
dppiv
almost
undetect
level
six
scc
sampl
fig
comparison
statist
signific
variat
dppiv
level
seen
six
adc
sampl
fig
cancer
microenviron
fundament
differ
normal
tissu
prevail
model
activ
fibroblast
tumor
modifi
phenotyp
epitheli
cell
via
solubl
diffus
growth
factor
growth
factor
includ
acceler
cell
prolifer
modifi
extracellular
matrix
promot
angiogenesi
increas
inflammatori
cell
recruit
proteolyt
process
dppiv
may
repres
defens
mechan
mitig
activ
normal
cell
fig
provid
evid
activ
regul
proteolyt
process
dppiv
attenu
signal
may
achiev
reduct
activ
increas
bind
fig
km
cleavag
dppiv
similar
rang
report
physiolog
substrat
dppiv
includ
gip
consequ
could
biolog
substrat
dppiv
final
dppiv
downregul
almost
undetect
level
scc
wherea
signific
chang
dppiv
level
adc
suggest
separ
mechan
underli
develop
two
cancer
subtyp
dramat
reduct
dppiv
scc
suggest
elev
level
intact
may
present
tumor
nich
cancer
subtyp
fig
play
critic
role
acceler
earli
carcinogenesi
overexpress
associ
hyperplasia
neoplasia
earli
stage
sever
anim
model
contrari
reduc
express
link
reduct
cancer
format
metastasi
human
popul
studi
higher
level
circul
associ
cancer
type
includ
colorect
prostat
breast
cancer
express
level
regul
affect
cancer
format
progress
homeostasi
microenviron
crucial
mainten
proper
cellular
prolif
inhibitori
activ
higher
level
intact
absenc
dppiv
might
contribut
earli
carcinogenesi
lung
scc
catalyt
effici
dppiv
close
report
catalyt
effici
mmp
kcatkm
dppiv
mmp
slow
catalyt
rate
might
characterist
critic
extracellular
proteas
maintain
homeostasi
stromal
microenviron
cleavag
slow
take
hour
unclear
whether
reason
past
failur
observ
cleavag
dppiv
vitro
recent
faidley
et
al
report
signific
chang
circul
level
dppiv
inhibitor
sitagliptin
administ
pig
three
day
remain
investig
stabl
vivo
whether
measur
composit
intact
truncat
protein
interact
shown
studi
also
consist
result
crystal
variou
biochem
studi
residu
interact
igfbp
locat
b
residu
domain
residu
base
cocryst
structur
either
ntermin
ctermin
domain
igfbp
sever
residu
seem
engag
interact
mutat
residu
significantli
reduc
bind
igfbp
sitedirect
mutagenesi
bind
assay
suggest
bind
occur
c
domain
differ
bind
igfbp
therefor
weaker
activ
probabl
attribut
conform
chang
caus
lack
two
amino
acid
amino
terminu
reduct
ligand
concentr
blockad
bind
promis
anticanc
strategi
result
suggest
proteolyt
process
anoth
altern
way
control
igf
axi
consist
express
dppiv
proteas
reduc
certain
cancer
type
eg
human
lung
scc
dppiv
inhibitor
current
use
treat
human
type
ii
diabet
potenti
longterm
impact
balanc
cell
growth
apoptosi
nich
warrant
investig
